Bayer HealthCare Ranks Top In China
This article was originally published in PharmAsia News
Executive Summary
Bayer HealthCare may rank 10 on the global pharmaceutical market, but according to research firm IMS's Q1 2008 figures, the firm's prescription drug revenue was top in China. The result was corroborated by China's R&D-based Pharmaceutical Association Committee's Q1 figures. The acquisition of Topsun Science and Technology's OTC business has raised Bayer's profile in the country and will double its OTC sales. Bayer China discloses that Bayer HealthCare revenue in the country is expected to grow 40 percent this year to over RMB 4.5 billion ($658.8 million). However, there are soft spots such as the gynecology sector, which fails to capitalize on the firm's global strength to translate into significant sales in China. Also, investment in local community health services will need time for the results to be seen. (Click here for more - Chinese Language)
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.